BioLife Solutions Reports Second Quarter 2018 Preliminary Revenue of $5.2 Million, up 103% Year-over-Year and 36% Sequentially

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. SPCX
10. AZN

Go back to BioLife Solutions Reports Second Quarter 2018 Preliminary Revenue of $5.2 Million, up 103% Year-over-Year and 36% Sequentially

BioLife Solutions (BLFS) PT Raised to $18 at Maxim Group as Cell Media Revs Beat Expecations

July 2, 2018 11:04 AM EDT

Maxim Group raised its price target on BioLife Solutions (NASDAQ: BLFS) to $18.00 (from $12.00) while maintaining a Buy rating.

Analyst Jason McCarthy highlighted:

BioLife shares are up today (15%+) following the company's announcement of preliminary cell preservation media revenue for 2Q18 coming in at $5.2M, up 36% sequentially and 103% y/y. The company raised guidance to $18.5M-$20M, from $14.5M-$15.5M. The company is... More

BioLife Solutions (BLFS) Reports Prelim. 2Q Revenues Above Consensus; Boosts FY18 Revenue Guidance

July 2, 2018 8:10 AM EDT

BioLife Solutions (NASDAQ: BLFS) reported Q2 revenue for the quarter came in at $5.2 million versus the consensus estimate of $3.7 million.

BioLife CEO Mike Rice commented, "Strong product demand during the second quarter from our cell and gene therapy customers in the regenerative medicine market segment resulted in more than 100% revenue growth over the prior-year period. Given our performance for the first half of 2018, increased adoption of our products in cell therapy clinical trials, and our outlook on product demand for the remainder of the year, we are significantly... More